1. Introduction {#sec1}
===============

Abdominal aortic aneurysm (AAA) affects a high percentage of the aged population in industrialized countries and mortality rates associated with rupture of AAA are high. The aetiology of AAA is essentially unknown, but it is generally accepted that environmental and genetic factors contribute substantially to the risk of AAA \[[@B1]\]. An association between AAA and atherosclerosis has long been recognized. There are, however, histological and epidemiologic differences between the two diseases. The major risk factors for AAA are increasing age, family history, male gender, hyperlipidemia (HL), arterial hypertension (HTN), and smoking \[[@B1]\]. Of these, smoking seems to be the most relevant, with a considerably higher risk for AAA than for atherosclerosis \[[@B2]\]. Diabetes mellitus (DM) is a well-established risk factor for atherosclerosis and has been reported to be protective for AAA \[[@B3]\]. Studying the influence of cardiovascular risk factors, particularly those that differentially influence AAA and atherosclerosis, could help to ascertain the causes of AAA.

Human AAA is characterized by leukocyte infiltration into adventitia and media and depletion of vascular smooth muscle cells (VSMC) in the media. Another relevant feature of the disorder is a decrease in AAA wall strength caused by the breakdown of elastic fibres and the hypervascularization of aortic tissue \[[@B4]\]. A key factor in the pathophysiology of AAA is PGE~2~. PGE~2~ induces expression of metalloproteinases and inhibits the production of macromolecules of the extracellular matrix \[[@B5], [@B6]\]. It acts as a signalling molecule in response to proangiogenic factors and also induces release of several angiogenic factors in a manner of positive loop \[[@B7]--[@B10]\]. Consequently, inhibition or deletion of the enzymes involved in the biosynthetic pathway of PGE~2~ interferes in AAA development in animal models \[[@B11]--[@B15]\].

PGE~2~ biosynthesis begins with the formation of PGH~2~ from arachidonic acid (AAc) catalyzed by cyclooxygenase (COX). PGH~2~ is in turn isomerized to PGE~2~ by PGE-synthases (PGES) \[[@B16]\]. The microsomal isoform of PGES, mPGES-1, is inducible by proinflammatory cytokines and it seems to be the essential PGES isoenzyme involved in PGE~2~ biosynthesis under inflammatory conditions \[[@B17]--[@B19]\]. COX-2/mPGES-1 is widely regarded as the main contributing enzymatic tandem for PGE~2~ biosynthesis under pathological conditions.

PGE~2~ exerts its cellular effects by binding to four distinct E-prostanoid receptors (EP1--4). EPs belong to the family of seven transmembrane G protein-coupled rhodopsin-type receptors. Each receptor has different and often opposing biological effects. EP2 and EP4 are Gs proteins-coupled receptors and they upregulate intracellular cAMP levels. EP3 usually counteracts EP2- and EP4-mediated upregulation of cAMP by preferentially coupling to Gi proteins \[[@B20]\]. Also, interventions on the PGE~2~ receptor display benefits in experimental AAA \[[@B21], [@B22]\].

We recently reported that COX-2, mPGES-1, EP-2, and EP-4 are upregulated in AAA and that the COX-2/mPGES-1/EP-4 axis could play a relevant role in AAA-associated hypervascularization from the early stages of AAA development \[[@B23]\]. However, information is lacking regarding the influence of cardiovascular risk factors on local levels of the COX-2/mPGES-1/EP-4 axis in AAA.

In this study, we aimed to evaluate the influence of major cardiovascular risk factors on the PGE~2~ pathway in human abdominal aortic aneurysms.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

The inclusion criteria for this study were patients who underwent open repair for AAA with an atherosclerotic aneurysm and in whom an infrarenal aorta biopsy was taken during the intervention. The exclusion criteria were absence or inadequate aortic biopsy, pseudoaneurysms, and infectious or inflammatory aneurysms. All patients underwent surgery at Hospital de la Santa Creu i Sant Pau (HSCSP). The study was approved by the local ethics committee, and informed consent was obtained from each patient. All procedures were reviewed by the institutional review board at HSCSP. The investigation conforms with the principles outlined in the Declaration of Helsinki.

2.2. Tissue Samples {#sec2.2}
-------------------

Samples were obtained from remaining midinfrarenal aortic wall after exclusion and prosthetic replacement of AAA. When luminal thrombus was present it was separated before the aorta biopsy was taken and aortic tissue was washed twice with cold phosphate buffered saline (PBS). A portion of each sample was placed in RNAlater solution (Qiagen GmbH, Hilden, Germany) and stored at 4°C for 24 hours before long-term storage at −80°C until further processing for RNA isolation. When possible a portion was fixed in formalin solution 10% (Sigma-Aldrich, Inc., St. Louis, MO) for 24 h and included in paraffin for immunohistochemical studies.

2.3. Risk Factors Definitions {#sec2.3}
-----------------------------

The risk factors definitions used in this study were diabetes mellitus (DM): glycated haemoglobin \>5.8% or use of oral antidiabetic drugs or insulin; arterial hypertension (HTN): systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥80 mm Hg, or use of antihypertensive medication; hyperlipidemia (HL): a total cholesterol \>6.2 mmol/L, LDL cholesterol \>1.70 mmol/L, or triglycerides \>1.65 mmol/L; smoking: categorized into 2 groups: current smoking (CS): smokers and ex-smokers who stopped smoking \<1 year and noncurrent smoking (N-CS): never-smokers and ex-smokers who stopped smoking \>1 year; chronic occlusive pulmonary disease (COPD): FEV1/FVC \< 0.7; and renal insufficiency (RI): estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m^2^ calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@B24]\].

2.4. Analysis of mRNA Levels in the Tissues and Culture Cells {#sec2.4}
-------------------------------------------------------------

Tissues were homogenized in the FastPrep-24 homogenizer and Lysing Matrix D tubes (MP Biomedicals, Solon, OH). RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) following the manufacturer\'s instructions. cDNA was prepared by reverse transcription of 1 *μ*g RNA using High-Capacity cDNA Archive kit with random hexamers (Applied Biosystems, Foster City, CA). mRNA expression of the selected genes was studied by real-time PCR in an ABI Prism 7900HT using predesigned validated assays (TaqMan Gene Expression Assays; Applied Biosystems) and universal thermal cycling parameters. Relative expression was expressed as transcript/*β*-actin ratios.

2.5. Plasma Levels of PGE~2~ {#sec2.5}
----------------------------

A sample of 10 mL of peripheral blood was collected in heparin-containing tubes. Blood was collected before anesthesia in the operating room. It was centrifuged immediately and plasma aliquoted and frozen at −80°C until analysis. PGE~2~ and 13,14-dihydro-15-oxo-PGE~2~ were determined using enzyme immunoassay (EIA) kits (Cayman Chemical, Ann Arbor, MI) following the manufacturer\'s instructions.

2.6. Immunohistochemistry {#sec2.6}
-------------------------

Immunohistochemical studies were performed using a rabbit polyclonal antibody against mPGES-1 (ref. HPA045064 prestige antibodies, diluted 1 : 50) from Sigma and a mouse monoclonal antibody anti-EP-4 (ref. 101775, diluted 1 : 100) from Cayman Chemical. Blanks were performed using the corresponding blocking peptides all from Cayman. Monoclonal antibodies (ref. M0616, diluted 1 : 35; ref. IR751 and ref. IR613, without further dilution) from Dako were used for von Willebrand Factor (vWF, endothelial cell marker), CD45 (pan-leukocyte marker), and CD68 immunostaining. Three-micrometer sections of paraffin-embedded tissue samples were stained in a Dako Autostainer Link 48 using the Dako EnVision Flex kit. Diaminobenzidine was used as chromogen. Immunostainings used for comparative purposes were processed simultaneously.

2.7. Statistical Analysis {#sec2.7}
-------------------------

SPSS and Sigma-Stat software were used for statistical analysis. All data regarding transcript levels are expressed relative to *β*-actin ×1000. All quantitative data in this study were nonnormally distributed and expressed as median (25th--75th percentile). We used the Mann-Whitney rank sum test to compare the two groups. The Pearson product moment correlation was used to evaluate the association between continuous variables after Log10 transformation of data with nonnormal distribution. Data were also analyzed using a multiple linear model including the effect of the identified risk factors and controlling possible confounding factors; a logarithmic transformation was applied to those outcomes without a normal distribution. A *P* value below 0.05 was considered significant.

3. Results {#sec3}
==========

From 2008 to 2012, 225 elective AAA were performed in our center (Department of Vascular and Endovascular Surgery of the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain). 166 patients underwent open surgery and 59 had endovascular aortic repair (EVAR). An adequate biopsy was obtained from 89 patients during the intervention.

[Table 1](#tab1){ref-type="table"} shows the number and characteristics of participants. None of the risk factors caused significant differences in either COX-1 or COX-2 levels between AAA samples ([Table 2](#tab2){ref-type="table"}). Regarding mPGES-1, only current smoking (CS) showed significant high transcript levels when compared with the noncurrent smokers (N-CS) group. mPGES-1 expression was higher in patients suffering COPD than in those without COPD, but the difference did not reach statistical significance. Next we evaluated the association between risk factors. Following *χ* ^2^ analysis, we identified COPD and HTN as variables likely related to CS. As these two variables could act as confounding factors ([Table 3](#tab3){ref-type="table"}), we applied multiple linear regression analysis. The relationship between CS and mPGES-1 remained stable even in the presence of the confounding factors (COPD and HTN) in the statistics (*P* = 0.03). We found that plasma levels of PGE~2~ in AAA patients were significantly enhanced in the CS group when compared with the N-CS group ([Table 4](#tab4){ref-type="table"}). None of the other risk factors analysed had statistically significant differences regarding circulating levels of PGE~2~. When confounding variables were taken into account, multiple linear regression analysis showed statistically significant differences between CS and N-CS groups (*P* = 0.012).

[Figure 1(a)](#fig1){ref-type="fig"} shows examples of leukocyte infiltration of AAA samples. Microvessels were abundant in the adventitia and in the media. While major infiltrated leukocytes (determined by CD45 immunostaining) systematically accumulated in perivascular areas of microvessels, macrophages (determined by CD68 immunostaining) displayed a more scattered pattern. Immunohistochemistry study of mPGES-1 was performed in AAA samples from 4 patients of each smoking group to localize the protein expression. No differences were observed between CS and N-CS groups regarding mPGES-1 protein location. mPGES-1 was located in MVEC, VSMC, and infiltrating leukocytes ([Figure 2(a)](#fig2){ref-type="fig"}). In an attempt to approach the origin of the differences of mPGES-1 in our AAA samples, we determined the statistical association of mPGES-1 transcript levels with cell-characteristic markers as independent variables. We analysed mRNA levels of von Willebrand Factor (vWF), *α*-actin, and CD68 as markers of endothelial cell, VSMC, and macrophages, respectively. No significant statistical association was found between mPGES-1 and CD68 transcript levels (not shown). In contrast, mPGES-1 levels significantly correlated with both *α*-actin and vWF ([Figure 2(b)](#fig2){ref-type="fig"}). We then explored the influence of CS on the cell markers and no significant differences were found between CS and N-CS (not shown).

Regarding PGE~2~ receptors, EP-1 was expressed only scarcely in AAA samples and therefore was not considered for the analysis of cardiovascular risk factors. No risk factor caused statistically significant variation of either EP-2 or EP-3. In contrast, significant differences between CS and N-CS groups were found regarding EP-4, CS having the highest transcript levels when simple statistical analysis was applied ([Table 5](#tab5){ref-type="table"}). Moreover, when confounding variables (COPD and HTN) were introduced in statistics the relationship between CS and EP-4 remained stable (*P* = 0.007). EP-4 was almost undetectable in VSMC in culture in terms of mRNA (78-fold lower than in MVEC, not shown). Immunohistochemical staining indicated that EP-4 was much less expressed in VSMC than in MVEC. EP-4 was detected mainly in MVEC and infiltrating leucocytes. No differences between CS and N-CS groups were observed regarding localization of EP-4 ([Figure 3(a)](#fig3){ref-type="fig"}). The association between EP-4 and CD68 transcript levels was poor ([Figure 3(b)](#fig3){ref-type="fig"}), whereas the association with vWF was stronger. In addition, we observed an excellent correlation between mPGES-1 and EP-4 transcript levels.

4. Discussion {#sec4}
=============

This is the first study to describe the influence of cardiovascular risk factors on local levels of PGE~2~ pathway in abdominal aortic aneurysm. We found that current smoking was associated with increased local expression of transcript levels of mPGES-1 in AAA.

In accordance with other reports, we recently found that local expression of COX-2 was increased in aneurismal tissue. Additionally, we reported that mPGES-1 was increased in AAA and that the upregulation of COX-2/mPGES-1 precedes maximal leukocyte infiltration \[[@B23]\]. We found that EP-2 and EP-4 were upregulated in AAA, whereas EP-3 was significantly downregulated. An interesting finding was that PGE~2~-mediated in vitro angiogenesis was fully dependent on EP-4. Herein, we report the influence of the most relevant cardiovascular risk factors on the COX-2/mPGES-1/EP-4 axis expression.

Current smoking was the only cardiovascular risk factor that was significantly associated with increased local expression of mPGES-1 in aneurysmatic aorta. However, it had no effect on COX-2 expression. This observation is consistent with the fact that COX-2 and mPGES-1 display different regulation in vitro \[[@B18], [@B19]\]. The increase in the expression of PGE~2~ biosynthetic machinery was consistent with the higher levels of PGE~2~ observed in the plasma of the smoker patients. Nevertheless, as AAA should be considered a systemic disease of the vasculature \[[@B1]\], other vascular territories may contribute to circulating levels of PGE~2~.

The presence of mPGES-1 in a particular cell is necessary for PGE~2~ biosynthesis \[[@B17]--[@B19], [@B25]\]. All vascular cells \[[@B17], [@B23], [@B26]\] and leukocytes \[[@B23]\], likely mainly macrophages, express mPGES-1. Our present results show that the expression levels of mPGES-1 correlate with the expression of vascular cell markers rather than with infiltrating macrophages markers suggesting that mPGES-1 is expressed in VSMC and MVEC as we reported before \[[@B17], [@B18], [@B26]\]. Therefore, changes in the number of VSMC and MVEC influence mPGES-1 levels. The absence of statistically significant differences between the CS and N-CS groups regarding transcript levels of vascular cell markers, together with increased levels of mPGES-1 in the CS group, strongly suggests that expression of mPGES-1 is effectively upregulated in vascular cells in CS group. Nevertheless, VSMC tends to be reduced whereas MVEC are substantially increased in AAA \[[@B1], [@B4], [@B26]\]. Altogether, our results heighten the role that MVEC-associated mPGES-1 and current smoking could have in AAA progression. Of course this does not rule out the important role of macrophages in AAA progression. Indeed, macrophage COX-2-derived PGE~2~ has been found to be relevant in the pathogenesis and rupture of AAA \[[@B12], [@B27], [@B28]\].

Regarding PGE~2~ receptors, only CS had an effect on the local levels of EP-4. Active smokers had significantly higher levels of EP-4 transcript. EP-4 is the most abundant subtype of PGE~2~ receptor in endothelial cells and it is a key receptor for PGE~2~-induced angiogenesis \[[@B23]\]. It was expressed in leukocytes, but we found that variation of EP-4 expression correlated better with vWF mRNA levels (endothelial cell marker) than with CD68 (macrophage marker). The statistical significance of the difference between CS and N-CS regarding mPGES-1/EP-4 axis was maintained after the introduction of HTN and COPD as confounding variables in the statistics. Moreover, the association of mPGES-1 and EP-4 transcript levels was highly significant. Taken together, our results support the concept that smoking substantially affects aortic vascular cells and suggest that MVEC are particularly affected.

Smoking is a particularly relevant risk factor for AAA \[[@B29]\]. It has been reported that the association between smoking and AAA is 2.5-fold higher than the association between smoking and coronary heart disease \[[@B2]\]. Tobacco smoke also enhances AAA formation in animal models \[[@B30], [@B31]\]. Our data indicated that mPGES-1/EP-4 is mainly linked to vascular cell state, whereas local levels of COX-2 depend on several factors such as the inflammatory infiltrate in the aortic wall. Local levels of COX-2 were not associated with any particular marker. Therefore, it seems that smoking affects the state of the vascular cells more than the degree of leukocyte infiltration. Many reports provide evidence supporting the association between renal function and atherosclerosis, and eGFR is an independent prognostic factor for cardiovascular disease \[[@B32]\]. We recently reported that eGFR is an excellent predictor of vascular events in patients with peripheral arterial disease \[[@B33]\]. Since RI could indicate the atherosclerosis level of patients, our results suggest that the effect of smoking on local levels of mPGES-1/EP-4 is independent of the atherosclerosis and COPD states of patients with AAA. These results support the lack of association of COPD and AAA with smoking described in a previous report \[[@B34]\]. More research is needed to ascertain the molecular species and signalling pathways involved in the effect of tobacco smoke on the induction of mPGES-1 and EP-4 expression in human AAA.

In conclusion, we show for the first time that current smoking increases MVEC-associated mPGES-1/EP-4 and provides further insight into the relevance of tobacco smoking in AAA development. Our data are consistent with reports showing that suppression of either mPGES-1 or EP-4 expression reduces AAA development in animal models \[[@B15], [@B21], [@B22]\] and reinforce the potential of mPGES-1 and EP-4 as alternative targets for therapy in AAA patients.
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![Representative immunohistochemical images of vWF (endothelial cell marker), CD45 (pan-leukocyte marker), and CD68 (macrophage marker) in aorta samples from two AAA patients. Red arrow-ends indicate some immunostained cells. Size bars: 500 *μ*m. In upper panels black-tipped arrows are used to orient the position of the vessel by indicating to where intima and adventitia are.](MI2014-316150.001){#fig1}

![(a) Representative immunohistochemical images of mPGES-1 in aorta samples from current smokers (CS, left) and noncurrent smokers (N-CS, right) patients, showing mPGES-1 immunostaining of MVEC (A, A′), VSMC of the media layer (B, B′), and mPGES-1 positive leukocytes (C, C′). Red arrow-ends indicate some immunostained cells. Size bars: 50 *μ*m. (b) Correlation between mPGES-1 transcript levels and those of vascular cell markers; Pearson product moment correlation applied to log 10-transformed data (*n* = 89).](MI2014-316150.002){#fig2}

![(a) Representative immunohistochemical images of EP-4 in aorta samples from current smokers (CS, left) and noncurrent smokers (N-CS, right) patients, showing EP-4 immunostaining of MVEC (A, A′), the scarce presence of EP-4 immunostaining in media layer in areas free of leucocyte infiltration (B, B′), and EP-4 positive leukocytes (C, C′). Red arrow-ends indicate some immunostained cells. Size bars: 50 *μ*m. (b) Correlation between mPGES-1 transcript levels and those of endothelial cell and macrophage markers and between EP-4 and mPGES-1; Pearson product moment correlation applied to log 10-transformed data (*n* = 89).](MI2014-316150.003){#fig3}

###### 

Clinical characteristics of individuals with AAA included in the study, demographics, and risk factors.

  ------------------------------------------------------------
  Measurements\                   mRNA         Plasma levels
  characteristic                               
  ------------------------------- ------------ ---------------
  Number                          89           79

  Aortic diameter (mm)            66 ± 12.7    64.3 ± 11.6

  Age (years)                     71.1 ± 6.5   72.4 ± 6.8

  Male                            87 (97.8%)   75 (94.9%)

  Diabetes mellitus               19 (21.3%)   21 (26.6%)

  Hypertension                    63 (70.8%)   60 (75.9%)

  Hyperlipidemia                  54 (60.7%)   51 (64.6%)

  Smoking habits                                

   Noncurrent smokers             63 (70.8%)   60 (75.9%)

   Current smokers                26 (29.2%)   19 (24.1%)

  Coronary artery disease (CAD)   20 (22.4%)   22 (27.9%)

   Angor pectoris                 2 (2.2%)     4 (5.1%)

   Myocardial infarction          6 (6.7%)     6 (7.6%)

   Coronary intervention/CABG     12 (13.5%)   12 (15.2%)

  Chronic renal insufficiency     34 (38.2%)   23 (29.1%)

  Dialysis                        0            0

  Peripheral vascular disease     48 (53.9%)   45 (57%)

   Absence pulses                 31 (34.8%)   30 (38%)

   Intermittent claudication      17 (19.1%)   15 (19%)

  Cerebrovascular disease         7 (7.9%)     7 (8.8%)

   Cerebral vascular attack       4 (4.5%)     5 (6.3%)

   Transient ischemic attack      3 (3.4%)     2 (2.5%)

  COPD                            26 (29.2%)   17 (21.5%)

  Antiplatelet users              47 (53.4%)   48 (61.5%)

  Statins users                   57 (64%)     58 (73.4%)

  ACEIs users                     23 (20.7%)   24 (30.8%)

  NSAD users                      6 (6.7%)     3 (3.8%)

  Corticoid users                 6 (6.7%)     4 (5.1%)

  Immunosuppressors               4 (3.5%)     2 (2.5%)
  ------------------------------------------------------------

Nominal variables are presented as number and as percentage (%) and continuous variables as mean ± SD. Aortic diameter: aneurysm maximum transverse diameter in mm; chronic renal insufficiency: estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^; noncurrent smokers: never smokers or quit smoking \>1 year; CABG: coronary artery bypass grafting; COPD: chronic occlusive pulmonary disease.

###### 

Transcript levels of COX isoenzymes and mPGES-1 in the AAA samples stratified by cardiovascular risk factors. The number of patients in every group is indicated in [Table 1](#tab1){ref-type="table"}. Data are expressed as relative to *β*-actin x1000.

                            Median   25th--75th percentile   *P* value versus no-factor^a^
  ------------------------- -------- ----------------------- -------------------------------
  COX-1                                                       
   No current smoking       10.7     7.68--14.3               
   Current smoking          11.6     9.47--18.7              0.109
   No renal insufficiency   10.9     8.50--16.3               
   Renal insufficiency      10.7     7.78--15.8              0.896
   No hypertension          10.8     9.62--16.1               
   Hypertension             10.7     7.49--15.8              0.419
   No diabetes mellitus     11.0     8.67--15.9               
   Diabetes mellitus        9.71     6.48--15.1              0.365
   No hyperlipidemia        12.3     8.20--16.1               
   Hyperlipidemia           10.6     8.39--14.3              0.457
   No COPD^b^               11.0     8.45--15.9               
   COPD                     10.4     8.07--15.3              0.695
  COX-2                                                       
   No current smoking       10.1     4.68--15.8               
   Current smoking          10.3     5.34--17.6              0.604
   No renal insufficiency   9.27     5.25--18.7               
   Renal insufficiency      10.9     5.30--14.6              0.678
   No hypertension          8.57     5.09--16.7               
   Hypertension             10.4     5.70--16.0              0.695
   No diabetes mellitus     9.27     4.70--15.9               
   Diabetes mellitus        11.6     6.90--24.7              0.188
   No hyperlipidemia        9.28     5.36--16.5               
   Hyperlipidemia           10.6     5.09--15.8              0.990
   No COPD^b^               10.1     5.20--16.5               
   COPD                     10.6     5.60--15.0              0.889
  mPGES-1                                                     
   No current smoking       2.42     1.16--4.08               
   Current smoking          3.46     2.33--4.95              0.009
   No renal insufficiency   2.69     1.24--3.82               
   Renal insufficiency      2.69     1.90--4.67              0.245
   No hypertension          2.87     1.74--3.67               
   Hypertension             2.66     1.48--4.46              0.735
   No diabetes mellitus     2.78     1.50--4.26               
   Diabetes mellitus        2.47     1.20--4.36              0.606
   No hyperlipidemia        2.66     2.06--3.65               
   Hyperlipidemia           2.76     1.20--4.51              0.798
   No COPD^b^               2.39     1.16--4.09               
   COPD                     2.90     2.35--4.75              0.06

^a^Mann-Whitney Rank Sum Test.

^b^Chronic obstructive pulmonary disease.

###### 

*χ* ^2^ analysis of risk factors.

  Variable      COPD              CS                DM                 HL                 RI
  ------------- ----------------- ----------------- ------------------ ------------------ -----------------
  HTN           *χ* ^2^ = 1.494   *χ* ^2^ = 3.371   *χ* ^2^ = 1.801    *χ* ^2^ = 0.0318   *χ* ^2^ = 4.448
  *P* = 0.222   *P* = 0.066       *P* = 0.180       *P* = 0.859        *P* = 0.035        
                                                                                          
  COPD                            *χ* ^2^ = 8.464   *χ* ^2^ = 0.0006   *χ* ^2^ = 0.082    *χ* ^2^ = 9.952
                *P* = 0.004       *P* = 0.981       *P* = 0.775        *P* = 0.002        
                                                                                          
  CS                                                *χ* ^2^ = 0.0326   *χ* ^2^ = 0.0009   *χ* ^2^ = 1.223
                                  *P* = 0.857       *P* = 0.976        *P* = 0.269        
                                                                                          
  DM                                                                   *χ* ^2^ = 2.55     *χ* ^2^ = 0.04
                                                    *P* = 0.110        *P* = 0.842        
                                                                                          
  HL                                                                                      *χ* ^2^ = 0.003
                                                                       *P* = 0.957        

HTN: arterial hypertension; COPD: chronic occlusive pulmonary disease; CS: current smoking; DM: diabetes mellitus; HL: hyperlipidemia; RI: renal insufficiency.

###### 

Plasma levels of PGE~2~ in the AAA samples stratified by cardiovascular risk factors. The number of patients in every group is indicated in [Table 1](#tab1){ref-type="table"}. Plasma levels of PGE~2~ are expressed as pg/mL.

                            Median   25th--75th percentile   *P* value versus no-factor^a^
  ------------------------- -------- ----------------------- -------------------------------
  Plasma-PGE~2~                                               
   No current smoking       55.9     39.3--71.1               
   Current smoking          68.0     57.1--119.5             0.008
   No renal insufficiency   58.4     44.0--71.4               
   Renal insufficiency      59.4     39.3--104.3             0.786
   No hypertension          70.1     53.0--95.2               
   Hypertension             56.2     39.4--77.2              0.140
   No diabetes mellitus     56.5     38.6--94.9               
   Diabetes mellitus        60.7     55.8--68.8              0.294
   No hyperlipidemia        55.8     44.5--101.9              
   Hyperlipidemia           60.7     41.2--72.0              0.947
   No COPD^b^               59.4     43.3--74.3               
   COPD                     57.1     43.5--115.9             0.807

^a^Mann-Whitney rank sum test.

^b^Chronic occlusive pulmonary disease.

###### 

Transcript levels of PGE receptors in the AAA samples stratified by cardiovascular risk factors. The number of patients in every group is indicated in [Table 1](#tab1){ref-type="table"}. Data are expressed as relative to *β*-actin x1000.

                            Median   25th--75th percentile   *P* value versus no-factor^a^
  ------------------------- -------- ----------------------- -------------------------------
  EP-2                                                        
   No current smoking       3.98     2.53--8.63               
   Current smoking          4.84     2.42--7.46              0.811
   No renal insufficiency   3.98     2.66--9.05               
   Renal insufficiency      4.49     2.41--7.72              0.653
   No hypertension          4.58     2.42--8.22               
   Hypertension             4.10     2.56--8.41              0.946
   No diabetes mellitus     3.98     2.45--7.24               
   Diabetes mellitus        5.27     2.88--23.6              0.115
   No hyperlipidemia        3.91     2.38--6.60               
   Hyperlipidemia           5.31     2.82--12.0              0.068
   No COPD^b^               3.98     2.51--9.82               
   COPD                     4.95     2.60--7.46              0.846
  EP-3                                                        
   No current smoking       2.80     1.30--6.18               
   Current smoking          3.41     2.16--6.32              0.202
   No renal insufficiency   2.68     1.47--4.74               
   Renal insufficiency      3.36     1.94--8.02              0.172
   No hypertension          3.12     1.98--5.74               
   Hypertension             3.06     1.45--6.30              0.484
   No diabetes mellitus     3.18     1.87--5.67               
   Diabetes mellitus        1.94     0.64--10.4              0.305
   No hyperlipidemia        3.47     1.82--7.19               
   Hyperlipidemia           2.54     1.46--5.32              0.288
   No COPD^b^               3.16     1.49--6.05               
   COPD                     2.95     1.92--6.21              0.853
  EP-4                                                        
   No current smoking       4.29     3.24--6.49               
   Current smoking          5.93     4.87--8.92              0.007
   No renal insufficiency   4.63     3.47--6.25               
   Renal insufficiency      5.70     3.45--7.72              0.259
   No hypertension          4.89     3.94--7.72               
   Hypertension             4.93     3.45--6.61              0.394
   No diabetes mellitus     4.92     3.48--6.66               
   Diabetes mellitus        4.71     1.82--7.96              0.678
   No hyperlipidemia        4.90     3.26--6.61               
   Hyperlipidemia           4.91     3.51--7.32              0.678
   No COPD^b^               4.90     3.52--6.57               
   COPD                     5.20     2.41--7.61              0.896

^a^Mann-Whitney rank sum test.

^b^Chronic obstructive pulmonary disease.

[^1]: Academic Editor: Jonathan Peake
